Amplify Weight Loss Drug & Treatment ETF is a ETF series of Amplify ETF Trust (series S000085024). Net assets $4.2M as of 2026-03-31. Index fund.
Showing 15 of 21 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| Novo Nordisk A/S | — | $494K | 1188.83% |
| Eli Lilly & Co | — | $480K | 1156.39% |
| Regeneron Pharmaceuticals Inc | — | $281K | 677.38% |
| Amgen Inc | — | $260K | 627.11% |
| Chugai Pharmaceutical Co Ltd | — | $249K | 599.68% |
| CSPC Pharmaceutical Group Ltd | — | $209K | 503.20% |
| Arrowhead Pharmaceuticals Inc | — | $206K | 496.39% |
| AbbVie Inc | — | $197K | 475.12% |
| AstraZeneca PLC | — | $193K | 465.51% |
| Pfizer Inc | — | $192K | 461.79% |
| Merck & Co Inc | — | $186K | 447.91% |
| Shionogi & Co Ltd | — | $185K | 446.41% |
| Roche Holding AG | — | $185K | 446.17% |
| Innovent Biologics Inc | — | $184K | 443.39% |
| Invesco Government & Agency Po | — | $123K | 296.52% |
| Report date | Net assets |
|---|---|
| 2026-03-31 | $4.2M |
| 2025-12-31 | $2.8M |
| 2025-09-30 | $3.1M |
| 2025-06-30 | $2.9M |
| 2025-03-31 | $3.9M |
| 2024-12-31 | $4.1M |
| 2024-09-30 | $4.8M |
| 2024-06-30 | $3.1M |